---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-237014"
form_type: "8-K"
ticker: "BNTC"
cik: "0001808898"
company_name: "Benitec Biopharma Inc."
filed_at: "2023-09-18T23:59:59+00:00"
generated_at: "2026-06-10T15:06:07.232515+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Benitec Biopharma increases CEO base salary to $655,200, Executive Director to $350,784

## Summary
- Dr. Jerel Banks' (CEO) base salary raised to $655,200, effective Oct 1, 2023.
- Megan Boston's (Executive Director) base salary raised to $350,784 (AUD converted at 0.64 USD/AUD), effective Oct 1, 2023.
- Salary increases approved by Compensation Committee on September 13, 2023.

## SEC filing metadata
- accession: 0001193125-23-237014
- form_type: 8-K
- ticker: BNTC
- cik: 0001808898
- company_name: Benitec Biopharma Inc.
- filed_at: 2023-09-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808898/000119312523237014/0001193125-23-237014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808898/000119312523237014/d552436d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-237014
- JSON: https://secwatch.observer/filing/0001193125-23-237014.json
- Plain text: https://secwatch.observer/filing/0001193125-23-237014.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.